Sign in
Taking people in United StatesPhase 4

Comparing 1 month and 6 months of two blood-thinning medicines after leg artery procedures

Compares 1 month with 6 months of dual antiplatelet therapy in peripheral arterial disease.

Key facts

Who runs it
Corewell Health West
Where
Detroit and Grand Rapids, United StatesSee the 2 sites
Trial code
Registry title
Vascular Trial Associated Registry Pilot
Status
Recruiting
Phase
Phase 4
People taking part
350 people, planned
Started
15 Oct 2025
Expected to end
30 Oct 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Clopidogrel (Plavix) Pharmacogenetic Test Reagents
Record updated
16 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with narrowed leg arteries caused by plaque (atherosclerosis) who are having, or recently had, a procedure to open leg arteries from inside the vessel (PVI). It compares 1 month vs. 6 months of aspirin plus clopidogrel.

Age
45 years or older
Sex
All sexes
Disease stage
Atherosclerotic vascular disease. The PVI must be scheduled or done in the last 30 days.
Earlier treatment
People on low dose rivaroxaban (2.5mg twice a day) with antiplatelet drugs can join only if they can stop these medicines.

Main reasons for not taking part

  • Allergy to clopidogrel or aspirin, or unable to stop clopidogrel for other medical reasons
  • High bleeding risk: past major bleeding, bleeding disorder, severe kidney problems (CrCl <30), platelet count <100,000, or blood thinners such as warfarin or full dose DOAC
  • Stroke within the last 6 months
  • Open bypass surgery at the same time as the procedure, or vessel disease not caused by plaque
  • Pregnant women, prisoners, or people who cannot give consent themselves

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Age greater than or equal to 45 at time of enrollment
  • Patient is scheduled for a PVI or has recently had a PVI in the last 30 days
  • Patient data is being submitted to Fivos, who is acting as the data collection subcontractor for the VQI-PVI registry
  • Atherosclerotic vascular disease

Who cannot take part

  • Patients on dual pathway inhibition (DPI) with low dose rivaroxaban (2.5mg twice a day) that are unable to stop these medications
  • Allergy to Clopidogrel
  • Allergy to aspirin
  • Nonatherosclerotic vascular disease
  • Patients with high bleeding risk (HBR) defined as:; History of major bleeding, active bleeding disorder, severe renal impairment (CrCl <30), concurrent anticoagulation, platelet count <100,000; Recent stroke (within 6 months); Current warfarin therapy or full dose therapeutic direct oral anticoagulants (DOAC)
  • Patients who cannot consent for themselves
  • Patients unable to stop clopidogrel for other medical reasons
  • Patients undergoing open bypass at the same time as the peripheral transcutaneous angioplasty
  • Patients unwilling or unable to comply with standard of care follow-up visits
  • Pregnant women
  • Prisoners

Where in United States

  • Henry Ford HospitalDetroit, United StatesContact: Sarah MeehanTaking people
  • Corewell Health WestGrand Rapids, United StatesContact: Stephen C Orey, MSTaking people

About the trial

What the trial wants to find out

The purpose of this investigator-initiated, multicenter, open label, randomized trial is to evaluate 1 month vs. 6 months of dual antiplatelet therapy (DAPT) in patients undergoing lower extremity endovascular revascularization. We hypothesize that extending dual antiplatelet therapy (DAPT) to six months, compared to one month, will improve patency rates of target vessels following peripheral vascular intervention (PVI) without significantly increasing complications, particularly bleeding events.

The 2 groups in the trial

  • Dual antiplatelet therapy 1-Month followed by single antiplatelet therapy indefinitelyExisting treatment, for comparison

    Aspirin and Clopidogrel (Plavix) for 1-month post-procedure followed by Aspirin indefinitely. Dual antiplatelet therapy (DAPT), defined as the use of Clopidogrel (75 mg/day) (Plavix) and aspirin (81 mg or more/day). Single antiplatelet therapy (SAPT), defined as the use of aspirin (81 mg or more/day).

    Treatment: Clopidogrel (Plavix) Pharmacogenetic Test Reagents

  • Dual antiplatelet therapy 6-Month followed by single antiplatelet therapy indefinitelyExisting treatment, for comparison

    Aspirin and Clopidogrel (Plavix) for 6-months post-procedure followed by Aspirin indefinitely. Dual antiplatelet therapy (DAPT), defined as the use of Clopidogrel (75 mg/day) (Plavix) and aspirin (81 mg or more/day). Single antiplatelet therapy (SAPT), defined as the use of aspirin (81 mg or more/day).

    Treatment: Clopidogrel (Plavix) Pharmacogenetic Test Reagents

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Vascular Trial Associated Registry Pilot: Antiplatelet Therapies for Patients Undergoing Lower Extremity Endovascular Revascularization
Plain-language title
Comparing 1 month and 6 months of two blood-thinning medicines after leg artery proceduresGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
16 July 2026